ArticleFrontiers in pharmacology2020

Prognosis of Lung Adenocarcinoma Patients With NTRK3 Mutations to Immune Checkpoint Inhibitors.

Yuchun Niu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.